Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fed Condition

NCT ID: NCT01053338

Last Updated: 2010-01-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30
• Study Completion Date: 2008-04-30

Brief Summary

To determine the single-dose oral bioequivalence study of Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil®PM, of Wyeth consumer health care, USA, in normal, healthy, adult, human subjects under fed conditions.

Detailed Description

Detailed Description : The study was conducted as an Open label, balanced, randomized, two-treatment, two-sequence, two period,single-dose, crossover oral bioequivalence study of Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil@PM, of Wyeth Consumer Healthcare, USA., in normal, healthy, adult, human subjects under fed conditions. A total number of forty (40) subjects were enrolled in the study and all the subjects completed both the periods of the study.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ibuprofen and Diphenhydramine Citrate

Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's

Group Type: EXPERIMENTAL

Ibuprofen and Diphenhydramine Citrate

Intervention Type: DRUG

Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets

Advil

Advil PM 200 mg/38 mg Tablets of Wyeth

Group Type: ACTIVE_COMPARATOR

Ibuprofen and Diphenhydramine Citrate

Intervention Type: DRUG

Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets

Interventions

Ibuprofen and Diphenhydramine Citrate

Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets

Intervention Type: DRUG

Other Intervention Names

Advil PM

Eligibility Criteria

Inclusion Criteria

• Healthy human subjects aged between 18 and 45 years (including both).
• Subjects with a BMI between 18.5 - 24.9 Kg/m2 (including both) but body weight not less than 45 Kgs.
• Subjects with normal health as determined by personal medical history, clinical examination, and laboratory examinations including serological tests.
• Subjects having normal 12 lead electrocardiogram (ECG).
• Subjects having normal chest X-Ray (P/A view).
• Subjects able to communicate effectively.
• Subjects willing to give written informed consent and adhere to all the requirements of this protocol.
• Female subjects who are postmenopausal or surgically sterile.
• Female subjects practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm,intrauterine device (IUD) or abstinence.

Exclusion Criteria

• Subjects having contraindications or hypersensitivity to Ibuprofen Diphenhydramine citrate or related group of drugs.
• History or presence of any medical conditions or disease according to the opinion of the physician.
• History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
• History or presence of significant alcoholism or drug abuse in the past one year.
• History or presence of significant smoking (more than 10 cigarettes or bidis/day or consumption of tobacco products).
• Difficulty with donating blood.
• Difficulty in swallowing solids like tablets or capsules.
• Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.
• Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
• Pulse rate less than 50 beats/minute or more than 100 beats/minute.
• Use of any prescribed medication during last two weeks or OTC medicinal products during the last one week preceding the first dosing.
• Major illness during 3 months before screening.
• Participation in a drug research study within past 3 months.
• Donation of blood in the past 3 months before screening.
• Female subjects demonstrating a positive pregnancy screen.
• Female subjects who are currently breast-feeding.
• Female subjects with child bearing potential using prohibited contraceptive method (Oral, Injectable or Implantable hormonal agents).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Dr. Reddy's Laboratories Limited

Principal Investigators

N. Netaji, MD

Role: PRINCIPAL_INVESTIGATOR

GVK Biosciences Pvt. Ltd

Locations

GVK Biosciences Pvt. Ltd

Amīrpet, Hyderabad, India

Countries

India

Other Identifiers

155-07

Identifier Type: -

Identifier Source: org_study_id